ライフサイエンスコーパス: fish oil

1 nd the concurrent decline of global sources (fish oils).

2 influenced by encapsulation of quercetin or fish oil.

3 p to 62% lower than other systems containing fish oil.

4 e oils a nutritional added value compared to fish oil.

5 g a control diet or a diet supplemented with fish oil.

6 nsaturated fatty acid (omega3 PUFA) enriched fish oil.

7 live oil, but not in those supplemented with fish oil.

8 rties and oxidative stability of spray-dried fish oil.

9 fter supplementation with olive oil, but not fish oil.

10 and EPA contents than yogurt containing free fish oil.

11 ls rich in SFA, unsaturated fat and SFA with fish oil.

12 racteristics than yogurt fortified with free fish oil.

13 rs of EPA/DHA and promising alternatives for fish oil.

14 s there was no change in the identity of the fish oils.

15 c PAHs, as well as two EPA indicator PAHs in fish oils.

16 inexpensive source of omega-3's, compared to fish oils.

17 Patients were randomized to receive fish oil (1-g capsules containing >/=840 mg n-3-PUFAs as

18 + 510 mg/day docosahexaenoic acid [DHA]), or fish oil (1000 mg/day EPA + 500 mg/day DHA) for 90 days,

19 + 510 mg/day docosahexaenoic acid [DHA]), or fish oil (1000 mg/day EPA + 500 mg/day DHA) for 90 days,

20 , 26), chondroitin (22%, 95% CI: 8, 33), and fish oil (16%, 95% CI: 0.3, 29).

21 -18.6+/-4.5 mOsmol/l; n = 18; P < 0.001) and fish oil (-19.8+/-3.9 mOsmol/l; n = 19; P < 0.001) suppl

22 ed fatty acids were the most concentrated in fish oils (25.3-30.8% and 36.1-45.0%).

23 Low-dose fish oil (3 capsules/day, 1080 mg eicosapentaenoic acid+

24 Patients were randomized to fish oil (4 g/day) or placebo and followed, on average,

25 re randomly assigned to receive DHA-enriched fish oil (800 mg/d) or vegetable oil capsules without DH

26 Subjects were randomized to receive enteral fish oil (9.75 g eicosapentaenoic acid and 6.75 g docosa

27 e containing all animal fat and another with fish oil added directly.

28 In contrast, study results of fish oil administration in critically ill patients are c

29 Enteral fish oil administration was associated with increased se

30 de protein hydrolysate, were able to protect fish oil against oxidation in an iron induced oxidation

31 herefore sought to determine whether enteral fish oil alone would reduce pulmonary and systemic infla

32 ntaenoic acid and docosahexaenoic acid) from fish oil ameliorate cardiovascular diseases.

33 Forty-one participants received fish oil and 49 received placebo.

34 Instead, fish oil and fenofibrate reduced circulating and hepatic

35 er diabetic conditions and by lipid-lowering fish oil and fenofibrate.

36 cid docosahexaenoic acid (DHA) is present in fish oil and has potent anti-inflammatory properties.

37 allate, and alpha-tocopherol in a bulk Kilka fish oil and its oil-in-water emulsion stabilized by soy

38 of the current supplements of DHA, including fish oil and krill oil, do not significantly increase br

39 f the primary outcome did not differ between fish oil and placebo recipients (48/99 [48%] vs 60/97 [6

40 VW-FO will address the increasing demand for fish oil and reduce pollution problems.

41 ants, to inhibit lipid oxidation in menhaden fish oil and structured lipid-based infant formula emuls

42 of oxidation in liposome model system and in fish oil and were high in phenolic content.

43 d and milk was compared with unencapsulated (fish oil) and microencapsulated omega3 PUFAs.

44 er, the role of serum omega-3 (from fish and fish oils) and omega-6 (from vegetable oils) polyunsatur

45 cial effects of dietary supplementation with fish oils, and offer new avenues for developing therapeu

46 -3 LC-PUFA levels are equivalent to those in fish oils, and represent a sustainable, terrestrial sour

47 droitin, saw palmetto, Ginko biloba, garlic, fish-oil, and fiber supplements were associated with tot

48 Combination lipid emulsions containing fish oil are associated with decreased bilirubin levels,

49 aturated fatty acids (n-3 PUFA), enriched in fish oils, are increasingly recognized to have potential

50 ndpoint occurred in 64.1% of patients in the fish oil arm and 63.2% of patients in the placebo arm (h

51 nd canola oil were evaluated as replacers of fish oil at three levels of inclusion (60%, 75% and 90%)

52 nd less cholesterol compared with a standard fish oil-based diet.

53 Based on Cox models, subjects receiving fish oil-based ILE experienced reversal of cholestasis 6

54 Fifty-one patients (81%) received a fish oil-based lipid emulsion (1 g/kg/d), 40 (63%) were

55 eview the most recent literature involving a fish oil-based lipid emulsion (FOLE) and its effects on

56 A fish-oil-based lipid emulsion (FOLE) as a component of P

57 buted to the omega-3 fatty acids in fish and fish oils, but toxic chemicals in fish may adversely aff

58 ticipants were randomly allocated to receive fish oil capsules (four 1-g capsules/d) or matching plac

59 (n = 368) was randomly allocated to receive fish oil capsules (providing 900 mg of n-3 LCPUFA daily)

60 270 mg/day eicosapentaenoic acid (EPA) from fish oil capsules or the placebo (olive oil capsules) fo

61 gleton pregnancy were provided with DHA-rich fish-oil capsules (800 mg DHA/d) or vegetable-oil capsul

62 ile receiving PN in 19 of 38 patients in the fish oil cohort versus 2 of 36 patients in the soybean o

63 Fish oil combined with milk fat, unlike unsaturated lipi

64 to high-fat meals containing EPA + DHA-rich fish oil compared with DHA-rich AO, but these difference

65 moisture content of beta-cyclodextrin/Danube fish oils complexes (common barbel, Pontic shad, Europea

66 All fish oils complied with a p-AV limit of 30, 98% with a P

67 with wrinkles was observed when the initial fish oil concentration was increased up to 50%.

68 With increasing initial fish oil concentration, melting point of the fish oil-lo

69 7.5%, w/w) was achieved at 50%, w/w, initial fish oil concentration.

70 PGE2 production decreases 50% when fish oil consumption produces tissue EPA/AA ratios of >/

71 etween fatty acids measured in late life and fish-oil consumption in early life, midlife, and late li

72 Daily fish-oil consumption in late life was associated with lo

73 Daily fish-oil consumption in midlife was associated with lowe

74 Fish-oil consumption was assessed by using validated que

75 Dietary fish oil containing omega3 fatty acids, eicosapentaenoic

76 ional analysis of triacylglycerols (TAGs) in fish oils containing eicosapentaenoic (EPA, 20:5) and do

77 ndations favor higher amino acid intakes and fish oil-containing lipid emulsions.

78 Fish oil contains a complex mixture of omega-3 fatty aci

79 acid (FA) composition in the skin by dietary fish oil could provide therapeutic benefits.

80 at the low PAH contamination of the selected fish oils could mainly occur by atmospheric sources.

81 We evaluated the efficacy of fish oil-derived n-3 (omega-3) PUFA therapy to slow the

82 Fish oil-derived n-3 PUFA therapy slows the normal decli

83 While fish oil did not induce oxidative acceleration, querceti

84 Fish oil did not reduce biomarkers of pulmonary or syste

85 educed in whey-sensitized donor mice fed the fish oil diet as compared to the control diet.

86 eOuJ female donor mice were fed a control or fish oil diet before and during oral sensitization with

87 Fish oil diet up-regulated hepatic CAT (activity and exp

88 -sensitized donor mice fed either control or fish oil diet were adoptively transferred to naive recip

89 An omega-3 PUFA-enriched HFD (referred to as fish oil diet, FOD) reduced inflammation in the obese ma

90 groups and received control, flaxseed oil or fish oil diets (10%w/w).

91 High-dose fish oil does not reduce AF recurrence in patients with

92 Furthermore, fish oil does not reduce inflammation or oxidative stres

93 Fish oil during early postnatal period may modulate the

94 repared with milk fat, soya bean oil or tuna fish oil during in vitro digestion with pancreatic lipas

95 bility to enteric damage and the benefits of fish oil during infection.

96 tion to obesity, maternal intake of DHA-rich fish oil during the second half of pregnancy does not af

97 women who were randomly assigned to receive fish oil during the third trimester of pregnancy, olive

98 n this study the two major n-3 PUFA found in fish oils, eicosapentaenoic (EPA) and docosahexaenoic (D

99 sules from double (DM) and multilayered (MM) fish oil emulsions were produced to evaluate the effect

100 ased more slowly than other fatty acids from fish oil emulsions.

101 ponent to enhance the oxidative stability of fish oil encapsulated in alginate-chitosan beads.

102 l characteristics and oxidative stability of fish oil encapsulated in filled hydrogel particles was d

103 s in stabilising capsule wall and protecting fish oil encapsulates from heat induced disruption and o

104 Fish oil encapsulates stabilised with gum arabic and sag

105 d caffeic acid was assessed in two different fish oil enriched food products: mayonnaise and milk.

106 Fish oil enriched mayonnaise with caffeates of medium al

107 Whereas in fish oil enriched milk emulsions the most effective caff

108 f this study is to determine whether dietary fish oil enriched with DHA (DFO) could reduce experiment

109 Feeding mice a fish oil-enriched diet completely restored hepatic Sort1

110 This suggests that fish oil-enriched diets disfavor AA oxygenation by alter

111 Lipid profiles of fish oil extracted from trout heads, spines and viscera

112 end, the following steps were conducted: (i) fish oil extraction, (ii) Omega-3 free fatty acids (FFA)

113 In addition, fish oil FAs prevent HF-induced electrophysiologic remod

114 we observe that C-22 FAs, including omega-3 fish oil FAs, have higher affinities for Ecat than Eallo

115 brown adipocytes, similar to cold-exposed or fish oil-fed brown fat.

116 nd brown thermogenesis was also confirmed in fish oil-fed C57/BL6 mice.

117 By contrast, splenocytes of fish-oil-fed whey-sensitized - but not sham-sensitized -

118 Feeding fish a fish oil finishing diet (FOFD) after grow-out on vegetab

119 mega-3 fatty acids (omega-3's), whether from fish oils, flax or supplements, can protect against card

120 wth trial compared a control diet containing fish oil (FO) as the main lipid source and different VO-

121 OP has been added to conventional fish oil (FO) feed at 4% and this was the OP diet, havin

122 Fish oil (FO) has antiinflammatory effects, which might

123 Olive oil (OO) and fish oil (FO) supplements have beneficial effects on end

124 As a novelty, EPA, DHA or fish oil (FO) were incorporated as omega-fatty acid sour

125 The replacement of fish oil (FO) with a DHA-rich Schizochytrium sp. algal m

126 D patients were randomised to receive either fish oil (FO), flaxseed oil (FSO) or corn oil capsules (

127 ) polyunsaturated fatty acids (LC-PUFA) from fish oil (FO), to compare with diets containing high lev

128 Fish oil (FO), which is rich in n-3 (omega-3) PUFAs, has

129 Fish oil (FO)-derived eicosapentaenoic acid (EPA) modula

130 The cardioprotective actions of the fish oil (FO)-derived long-chain n-3 polyunsaturated fat

131 lly limited marine ingredients, fishmeal and fish oil (FO).

132 in polyunsaturated fatty acids [contained in fish oil (FO)] and folate, are important in achieving no

133 and 50% SO], MSF (50% MCTs, 40% SO, and 10% fish oil (FO)], OS (80% olive oil and 20% SO), or MOSF (

134 nted (2.8% wt:wt) with corn oil (CO; n-6) or fish oil (FO; n-3) for 28 d.

135 Parenteral fish-oil (FO) therapy is a safe and effective treatment

136 Recent trials of fish oil for the prevention of atrial fibrillation (AF)

137 ospholipid (krill oil) and triacylglyceride (fish oil), for treating dry eye disease (DED).

138 g powder products that are easy-to-use solid fish oil formulation, which makes the handling and stora

139 Fish oils (FOs) have anti-inflammatory effects and lower

140 apeutic efficacy of individual components of fish oils (FOs) in various human inflammatory diseases s

141 lipid emulsion containing 10% fish oil or a fish oil-free lipid emulsion.

142 the potential to prevent PUFA in linseed or fish oil from ruminal biohydrogenation and oxidation dur

143 ts, suitable qualities to adequately replace fish oil from the perspective of fish performance and fi

144 , the rate of graft failure was lower in the fish oil group (3.43 vs 5.95 per 1000 access-days; incid

145 lar lavage fluid or plasma biomarkers in the fish oil group compared with the control group.

146 prescribed was significantly reduced in the fish oil group compared with the olive oil group (hazard

147 edication prescribed was also reduced in the fish oil group compared with the olive oil group (hazard

148 In the fish oil group, there were half as many thromboses (1.71

149 in the olive oil group, and 19 (4.9%) in the fish oil group.

150 nificantly different between the placebo and fish oil groups, including postoperative AF that was sus

151 the following order: corn oil approximately fish oil > orange oil > mineral oil > MCT.

152 triglycerides (MCT) > corn oil approximately fish oil > orange oil > mineral oil.

153 parenteral nutrition, patients who received fish oil had a faster time to ICU discharge alive (hazar

154 age, yogurt fortified with nano-encapsulated fish oil had a higher DHA and EPA contents than yogurt c

155 bean oil, patients who received olive oil or fish oil had a shorter time to termination of mechanical

156 High-dose fish oil has been explored in two randomised trials in d

157 Fish oil has been identified as one of the most importan

158 However, fish oil has not been tested independently in acute lung

159 Supplementation with fish oils has theoretical appeal for preventing these ou

160 docosahexanoic acid, omega-3 fatty acids in fish oil, has been associated with improved patient outc

161 Omega-3 fatty acids from fish oil have been associated with beneficial cardiovasc

162 Glutamine and fish oil have been shown to reduce mortality in general

163 Fish oils have many dietary benefits, but due to their s

164 -3 polyunsaturated fatty acids (contained in fish oil) have been shown to beneficially influence infe

165 e or an isocaloric HF diet supplemented with fish oil (HF-FO) for 12 weeks.

166 oleic sunflower oil (HF-omega9, N=11), 1.25% fish oil (HF-omega3, N=11), or no supplement (HF-control

167 r an HFD supplemented with 3% n-3 PUFAs from fish oil (HFD + FO) for 8 wk.

168 iers (NLC) containing tristearin and omega-3 fish oil, (ii) tristearin solid lipid nanoparticles (SLN

169 Although fish oil improved some relevant secondary outcomes such

170 However, increasing concentration of fish oil in a membrane might increase the acyl chain dyn

171 creasingly provided by aquaculture but using fish oil in feeds to supply n-3 LC-PUFA is unsustainable

172 ed crossover trial of low-dose and high-dose fish oil in participants with drug resistant epilepsy to

173 uce an oil containing n-3 LC-PUFA to replace fish oil in salmon feeds.

174 d emulsions are more suitable to encapsulate fish oil in terms of quantity of encapsulated oil, micro

175 , nano-liposome was used to nano-encapsulate fish oil in this study and encapsulated fish oil was uti

176 o delay iron catalyzed lipid oxidation in 5% fish oil in water emulsions and the 10-50kDa fraction wa

177 rst study on the nanoencapsulation of Danube fish oils in beta-cyclodextrin.

178 ybean, medium-chain triglyceride, olive, and fish oils in parenteral nutrition were compared using an

179 onal finite marine ingredients, fishmeal and fish oil, in farmed salmon diets with sustainable altern

180 id oxidation and protein partitioning in 10% fish oil-in-water emulsions prepared with different whey

181 valve homogeniser) on lipid oxidation in 10% fish oil-in-water emulsions prepared with two different

182 e and optical properties on the stability of fish oil-in-water emulsions to riboflavin-induced oxidat

183 lipid nanoparticles (SLN), and (iii) omega-3 fish oil-in-water emulsions was investigated.

184 and glycosylated alkyl gallates (C4-C18) on fish oil-in-water emulsions was studied.

185 nd oxidative stabilization of 5% (by weight) fish oil-in-water emulsions were investigated.

186 idation in liposome model system), and in 5% fish oil-in-water emulsions.

187 ers for the production of oxidatively stable fish oil-in-water emulsions.

188 This study shows that fish oil-in-water nanoemulsions can be formed from sunfl

189 Twelve arsenolipids were identified in the fish oil including three AsFAs and seven AsHCs.

190 evidence base include the roles of high-dose fish oil, inflammation, and oxidative stress in patients

191 patients with new hemodialysis grafts, daily fish oil ingestion did not decrease the proportion of gr

192 DESIGN, SETTING, AND PARTICIPANTS: The Fish Oil Inhibition of Stenosis in Hemodialysis Grafts (

193 tabolite CMPF was the strongest biomarker of fish oil intake.

194 s of human randomized controlled trials with fish-oil intervention during pregnancy and lactation gav

195 ls by aerogels was evaluated through loading fish oil into the non-blended aerogel.

196 tudy indicates that adding nano-encapsulated fish oil into yogurt gave closer characteristics to cont

197 outlook for single-cell organisms to replace fish oil is promising.

198 f polycyclic aromatic hydrocarbons (PAHs) in fish oils is complicated due to the fat matrix, which af

199 lowered with loading, which is mainly due to fish oil leakage.

200 rium partition data for diverse chemicals in fish oil, linseed oil, and goose fat at 37 degrees C.

201 replacing the soybean oil with a parenteral fish-oil lipid emulsion or emulsions of mixed-lipid sour

202 fish oil concentration, melting point of the fish oil-loaded particles shifted to lower onset melting

203 The highest fish oil loading efficiency (97.5%, w/w) was achieved at

204 Fish oil markedly enhanced EPA and DHA in mouse skin wit

205 The results indicate that low-dose fish oil may reduce seizures and improve the health of p

206 Maternal supplementation with fish oil might have prophylactic potential for long-term

207 y acid (FA) contents in a micro-encapsulated fish-oil (muEFO) supplement by using attenuated total re

208 rge multicentre randomised trial of low-dose fish oil (n-3 fatty acids <1080 mg/day) in drug resistan

209 tors, including vitamin B12, folic acid, and fish oil; obesity; and stress.

210 and naturally produced CyPG from the dietary fish-oil omega-3 polyunsaturated fatty acid eicosapentae

211 The dose of fish-oil/omega-3 PUFAs needed to achieve maximal target

212 y was to evaluate the influence of high-dose fish oil on AF recurrence, inflammation, and oxidative s

213 to detect any potential beneficial effect of fish oil on cognitive function in this study.

214 eneficial effects of dietary flaxseed oil or fish oil on streptozotocin-nicotinamide induced diabetic

215 The effect of dietary fish oil on weight gain and insulin sensitivity is depen

216 polyunsaturated fatty acids, commonly called fish oils) on the occurrence of clinical cardiovascular

217 lipids--vitamin A, beta-carotene and omega-3 fish oil--on the structural arrangement of solid lipid n

218 rtic constriction after the consumption of a fish oil or a control diet.

219 either with a lipid emulsion containing 10% fish oil or a fish oil-free lipid emulsion.

220 oad; the main exclusions were regular use of fish oil or absence of sinus rhythm at enrollment.

221 nt of the 3xTg-AD mice on high-fat diet with fish oil or curcumin or a combination of both for 4 mont

222 double-blinded manner with 3 g/day of either fish oil or olive oil for 4 weeks before sequential cham

223 of gestation to receive 2.4 g of n-3 LCPUFA (fish oil) or placebo (olive oil) per day.

224 The flavonol-rich fractions inhibited fish oil oxidation by 40-62% at a total phenolic concent

225 Inhibition of fish oil oxidation was studied using the thiobarbituric

226 significantly increased compared to the free fish oil (p<0.05).

227 ard the aquatic food chain, we also measured fish oil partition data at 7 degrees C.

228 Dietary supplementation with fish oil prevented transverse aortic constriction-induce

229 Forty-seven fish oil products available on the New Zealand market we

230 stark contrast to the very low percentage of fish oil products reported to be in compliance with prim

231 physiological and clinical effects, whether fish oil provides all the benefits of fish consumption,

232 infections was significantly reduced in the fish oil-receiving group (21.0% vs 37.2%, p = 0.035) and

233 The effect of fish oil recovered from fish visceral waste (FVW-FO) on

234 e supports that omega-3 dietary fatty acids (fish oil) reduce the risks of macular degeneration and c

235 Results indicated that the presence of fish oil reduced the crystallisation temperature, meltin

236 psy to explore whether low-dose or high-dose fish oil reduces seizures or improves cardiovascular hea

237 ch in saturated fatty acids) with or without fish oil (rich in n-3 PUFAs).

238 Dietary fish oils, rich in long-chain n-3 (omega-3) fatty acids

239 The potent odourants of the fish oil samples were obtained by solvent extraction fol

240 someric abundances of EPA and DHA in several fish oil samples.

241 samples of animal origin as shell powder and fish oil showed the highest concentrations of 56 and 29

242 1 transgenic mice and oral administration of fish oil, significantly promote interstitial Abeta clear

243 -chain triglycerides, 25% olive oil, and 15% fish oil (SMOF) with that of soybean oil (SO)-based lipi

244 We evaluated the influence of a fish-oil supplement over 5 mo on the kinetics of (13)C-D

245 Fish oil supplementation appeared to attenuate CAP-induc

246 Although it has been shown that fish oil supplementation enhances EPA (eicosapentaenoic

247 Fish oil supplementation had no statistically significan

248 with lower CVD risk, although the effects of fish oil supplementation remains inconsistent.

249 the plasma triglyceride concentration after fish-oil supplementation compared with placebo treatment

250 o of omega-6-to-omega-3 PUFA through diet or fish-oil supplementation during pregnancy.

251 Dietary fish-oil supplementation has been shown in human kinetic

252 Fish-oil supplementation increased numbers of EPCs and r

253 There was no significant effect of fish-oil supplementation on blood pressure, plasma lipid

254 We investigated effects of fish-oil supplementation on both classical and novel mar

255 contrast, there was a significant effect of fish-oil supplementation on cellular markers of endothel

256 Effects of genotype and fish-oil supplementation on the blood lipid profile, inf

257 Fish-oil supplementation successfully increased plasma n

258 al function, which indicated that effects of fish-oil supplementation were independent of eNOS genoty

259 cal study suggested that omega-3 fatty acid (fish oil) supplementation blunted cardiac responses to a

260 Importantly, switching to a fish oil-supplemented diet induced a recovery in DHA con

261 60 weeks, when frogs were then switched to a fish oil-supplemented diet.

262 upport an inverse association between use of fish oil supplements and inflammation.

263 d exposure study to evaluate the efficacy of fish oil supplements in attenuating adverse cardiac effe

264 ontent by a recently published assessment of fish oil supplements in New Zealand.

265 12% to 17%], P for trend < .001) and use of fish oil supplements increased from 1.3% to 12% (differe

266 Similar analyses for prenatal fish oil supplements showed no such association with aut

267 Three different commercial encapsulated fish oil supplements were evaluated by orthonasal sensor

268 valuation of sensory quality of encapsulated fish oil supplements, and might relate to the degree of

269 ificant role in the volatile fraction of the fish oil supplements.

270 3 groups: placebo (olive oil), krill oil, or fish oil supplements.

271 l mortality associated with a high intake of fish-oil supplements (HR: 0.83; 95% CI: 0.70, 1.00), but

272 in 3%); epistaxis associated with the use of fish-oil supplements (in 3%); and atrial fibrillation as

273 rivatives of p-hydroxybenzoic acid in a bulk fish oil system and its O/W emulsion were investigated.

274 t DHA may be the more bioactive component of fish oil that serves to disrupt lipid raft domain organi

275 However, the amount of fish oils that would have to be consumed to sustain chro

276 ietary supplementation with omega-3/6 PUFAs (fish oils) that have emerged from epidemiological studie

277 determined if enriching the maternal diet in fish oil, the primary source of EPA and DHA, affected ad

278 sted to concentrate omega-3 fatty acids from fish oils, under mild enzymatic conditions.

279 ociation with autistic disorder, even though fish oil use was associated with the same maternal chara

280 o-controlled trial of low-dose and high-dose fish oil versus placebo (corn oil, linoleic acid) in 24

281 CRP, 11% vs. -11%; DeltaMPO, -5% vs. -9% for fish oil vs. placebo, respectively; p value for interact

282 In some formulations, fish oil was added in order to study the effect of incre

283 Low-dose fish oil was also associated with a mild but significant

284 hase II randomised crossover trial, low-dose fish oil was effective in reducing seizures compared wit

285 Fish oil was encapsulated in hollow solid lipid micro- a

286 ctiveness in retarding lipid peroxidation in fish oil was evaluated by an accelerated stability test.

287 olysates (FPH) for the microencapsulation of fish oil was investigated.

288 l-in-water (O/W) emulsions containing 20%v/v fish oil was investigated.

289 Fish oil was loaded into the microcapsule core and prote

290 High-dose fish oil was no different than placebo in reducing seizu

291 Oxidative stability of the loaded fish oil was significantly increased compared to the fre

292 late fish oil in this study and encapsulated fish oil was utilized in fortifying yogurt.

293 parenteral nutrition, particularly olive and fish oil, was associated with improved clinical outcomes

294 ructure of gelatin and its adsorption at the fish-oil/water interface and to quantify the implication

295 nce on membrane fluidity, when quercetin and fish oil were encapsulated.

296 ared using long chain triglycerides (corn or fish oil) were most effective at increasing vitamin bioa

297 roup were given a typical diet containing 3% fish oil, whereas other groups were given the same diet

298 ega-3 LC-PUFA to serve as an alternative for fish oil, which was used as the 'golden standard'.

299 It has been previously reported that dietary fish oils, which are rich in the polyunsaturated fatty a

300 Replacement of fish oil with vegetable oil reduced formation of primary